Neuburgh Advisers LLC purchased a new stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,096 shares of the company’s stock, valued at approximately $143,000.
Several other hedge funds also recently bought and sold shares of the company. Coastal Investment Advisors Inc. grew its position in shares of Takeda Pharmaceutical by 59.8% in the second quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock valued at $32,000 after purchasing an additional 643 shares in the last quarter. Shelton Capital Management purchased a new position in Takeda Pharmaceutical in the first quarter worth approximately $46,000. Advisory Services Network LLC grew its position in Takeda Pharmaceutical by 101.6% in the second quarter. Advisory Services Network LLC now owns 2,076 shares of the company’s stock worth $37,000 after acquiring an additional 1,046 shares during the period. Global Retirement Partners LLC grew its position in Takeda Pharmaceutical by 63.3% in the first quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock worth $70,000 after acquiring an additional 1,326 shares during the period. Finally, Gabelli Funds LLC grew its position in Takeda Pharmaceutical by 0.4% in the second quarter. Gabelli Funds LLC now owns 348,712 shares of the company’s stock worth $6,172,000 after acquiring an additional 1,400 shares during the period. Institutional investors and hedge funds own 9.27% of the company’s stock.
NYSE:TAK traded up $0.25 during trading hours on Friday, reaching $17.43. 30,213 shares of the stock were exchanged, compared to its average volume of 1,006,431. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 1.01. The stock has a 50-day simple moving average of $17.10. Takeda Pharmaceutical Co Ltd has a twelve month low of $15.50 and a twelve month high of $21.95. The stock has a market cap of $26.67 billion, a P/E ratio of 34.11 and a beta of 0.70.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.